Non-myeloablative Hematopoietic Cell Transplantation (Mini-Allograft / Reduced Intensity Conditioning Transplant) — CPB 0634 | AETNA Coverage Update

TL;DR: Aetna, a CVS Health company, modified CPB 0634 governing non-myeloablative hematopoietic cell transplantation (mini-allograft / reduced intensity conditioning transplant) coverage policy, effective February 27, 2026. Here's what billing teams need to know.

This update to CPB 0634 Aetna's reduced intensity conditioning transplant policy clarifies which diagnoses qualify for covered mini-allograft procedures—and which ones land squarely in experimental, investigational, or unproven territory. The policy covers CPT codes 38204 through 38242 and HCPCS code S2150 for allogeneic stem cell harvest and transplantation, when selection criteria are met. If your team bills these codes for Aetna members, read this before your next prior authorization request.

Aetna Mini-Allograft Coverage Criteria and Medical Necessity Requirements 2026

The core logic of this Aetna non-myeloablative hematopoietic cell transplantation coverage policy is straightforward: mini-allograft is covered when a member can't tolerate a full conventional allogeneic transplant, but the underlying disease is one where conventional transplant is already an established treatment.

Aetna frames the mini-allograft as a "technical modification of an established procedure." That framing matters for your medical necessity documentation. You're not arguing that the mini-allograft itself is proven—you're arguing the patient needs the established transplant and the reduced-intensity approach is the only tolerable path.

To establish medical necessity, your documentation must do two things. First, it must establish that the patient's diagnosis falls on the covered indication list. Second, it must show the patient cannot tolerate a conventional allogeneic transplant with standard myeloablative conditioning. Missing either piece is a fast path to claim denial.

Prior authorization is standard for transplant procedures under most Aetna commercial plans. Don't submit CPT 38240 (hematopoietic progenitor cell transplantation) or CPT 38242 (allogeneic lymphocyte infusions) without a fully documented prior auth submission that cross-references the specific covered indication and the clinical rationale for reduced-intensity conditioning. If your transplant coordinator isn't already building that narrative into every auth packet, close that gap now.

The reimbursement stakes here are high. A single mini-allograft episode with associated harvest codes (38204–38215, 38230–38239), processing, and infusion can generate dozens of line items. A denial based on medical necessity or wrong indication reverberates across the entire claim series, not just one code.

Aetna Mini-Allograft Exclusions and Non-Covered Indications

This is where the policy draws a hard line. Aetna considers mini-allograft experimental, investigational, or unproven for diagnoses where even the conventional allogeneic transplant hasn't been established as effective. The logic holds: if the "full" version of the procedure isn't proven for a condition, the reduced-intensity version doesn't get a pass by association.

The excluded indication list includes conditions that might surprise some clinical teams. Breast cancer (ICD-10 C50.011–C50.929), melanoma (C43.0–C43.9), renal cancer, testicular cancer (C62.x series), and ovarian cancer all land in the experimental bucket. So do autoimmune diseases, acquired angioedema, essential thrombocythemia, polycythemia vera, and inherited hemophagocytic lymphohistiocytosis.

The real issue here is that some of these conditions—especially renal cell carcinoma—have historical clinical trial interest in mini-allograft approaches. Aetna is not moved by that history. Claims for those diagnoses will be denied as experimental regardless of the clinical rationale your physician submits. Don't waste a peer-to-peer appeal on a renal cancer mini-allograft claim against this policy.

If your institution runs clinical trials involving mini-allograft for excluded indications, work with your compliance officer to confirm those cases are billed under research billing pathways—not standard CPB 0634 coverage. The distinction matters, and blurring it creates audit exposure.

Coverage Indications at a Glance

Important: Each covered indication cross-references a separate Aetna CPB. Coverage for the mini-allograft approach depends on meeting the medical necessity criteria in that companion CPB, not just CPB 0634 alone. Your prior auth documentation needs to satisfy both policies.

Aetna Mini-Allograft Billing Guidelines and Action Items 2026

The effective date of February 27, 2026 means this policy is already active. If you haven't audited your mini-allograft billing against this version, do it now.

CPT, HCPCS, and ICD-10 Codes for Non-Myeloablative HCT Under CPB 0634

Covered CPT Codes (When Selection Criteria Are Met)

Covered HCPCS Codes (When Selection Criteria Are Met)

Key ICD-10-CM Diagnosis Codes

The policy lists 704 ICD-10-CM codes spanning both covered and excluded indications. Below are the primary groupings relevant to billing decisions. This is not a complete list—pull the full code set from CPB 0634 at app.payerpolicy.org/p/aetna/0634 before building your charge capture rules.

Experimental / Excluded Indications (High-Risk for Denial)

The remaining 600+ ICD-10 codes in the policy span the full range of covered hematologic malignancies, bone marrow failure syndromes, and solid tumor diagnoses included across the companion CPBs. The covered/excluded determination for any specific code depends on which indication group it maps to—not the code itself in isolation.

Build your charge capture rules around indication groups, not individual ICD-10 codes. A code like D46.x (myelodysplastic syndrome) points to CPB 0836 and a covered indication. A code like C43.x (melanoma) points to an excluded indication. The difference is the indication, and the ICD-10 is just how you document it.